Metastatic NSCLC Efficacy of TAGRISSO® (osimertinib)
Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer - European Journal of Cancer
Osimertinib versus Standard of Care EGFR TKI as First-Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset - Journal of Thoracic Oncology
TAGRISSO® (osimertinib) | AURA3 Study
Metastatic NSCLC Efficacy of TAGRISSO® (osimertinib)
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002) | Scientific Reports
TAGRISSO® (osimertinib) | AURA3 Study
Metastatic NSCLC Efficacy of TAGRISSO® (osimertinib)
Tagrisso® - Standard of Care for EGFR + Non Small Cell Lung Cancer - CancerConnect
Metastatic NSCLC Efficacy of TAGRISSO® (osimertinib)
TAGRISSO® (osimertinib) | FLAURA
Efficacy of TAGRISSO® (osimertinib) in resectable EGFRm NSCLC
a) Overall survival from LM diagnosis for the total population. (b)... | Download Scientific Diagram
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer | NEJM
Efficacy of Metastatic NSCLC – TAGRISSO® (osimertinib) Nurse Center
A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small-cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy -
TAGRISSO® (osimertinib) | FLAURA
New England Journal of Medicine publishes results of Phase III FLAURA trial in the 1st-line treatment of EGFR-mutated non-small cell lung cancer
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC | NEJM
TAGRISSO® (osimertinib) | AURA3 Study
Osimertinib Improves Overall Survival in Patients With EGFR-Mutated NSCLC With Leptomeningeal Metastases Regardless of T790M Mutational Status - Journal of Thoracic Oncology
Efficacy of TAGRISSO® (osimertinib) in resectable EGFRm NSCLC
Clinical Factors Affecting the Response to Osimertinib in Non-Small Cell Lung Cancer Patients with An Acquired Epidermal Growth Factor Receptor T790M Mutation: A Long-Term Survival Analysis | SpringerLink
Tagrisso demonstrates superiority over chemotherapy in EGFR T790M mutation-positive non-small cell lung cancer
